Form 4: Roivant Sciences CEO Reports Stock Transaction
Insider Transaction (Form 4)
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., reported a transaction in 13,909 shares of common stock on August 20, 2026.
Summary
- Tax/exercise-price withholding: disposed of 13,909 Common Shares at $36.84 ($512,408) on August 20, 2026; holds 1,599,154 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Eric Venker — Officer (President & Immunovant CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Tax/exercise-price withholding | Common Shares | 13,909 | $37 | $512.4K | 1,599,154 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Tax/exercise-price withholding (13,909 shares) |
Keywords
insider transaction, Form 4, ROIV, Roivant Sciences Ltd., neutral, Eric Venker
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.